Lineage Cell Therapeutics (LCTX) Asset Utilization Ratio (2011 - 2026)

Lineage Cell Therapeutics' Asset Utilization Ratio history runs 16 years deep, the most recent figure standing at 0.13 for Q1 2026.

• In Q1 2026, Asset Utilization Ratio rose 56.63% year-over-year to 0.13; the TTM figure through Mar 2026 stood at 0.13 (up 56.63% YoY), while the FY2025 annual figure was 0.13, up 45.39% from the prior year.
• Asset Utilization Ratio for Q1 2026 stood at 0.13, down from 0.14 in the prior quarter.
• The five-year high for Asset Utilization Ratio was 0.47 in Q3 2022, with the low at 0.06 in Q2 2024.
• The 5-year median for Asset Utilization Ratio is 0.1 (2023), against an average of 0.16.
• The sharpest annual moves came in 2022 and 2023: Asset Utilization Ratio soared 3078.23% in 2022, then plunged 82.87% in 2023.
• Lineage Cell Therapeutics' Asset Utilization Ratio stood at 0.12 in 2022, then declined by 25.17% to 0.09 in 2023, then rose by 4.86% to 0.09 in 2024, then jumped by 58.99% to 0.14 in 2025, then dropped by 7.56% to 0.13 in 2026.
• Business Quant data shows LCTX's Asset Utilization Ratio at 0.13 in Q1 2026, 0.14 in Q4 2025, and 0.12 in Q3 2025.